TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05006573

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

Cause of deathSlow enrollment Automatic label, confidence 0.5, unverified. How labels are made.
“Due to the decision to stop recruitment early, enrolment into the MAHALE trial was terminated in August 2022; 139 patients were screened and 100 randomised to IP.”

The sponsor’s own words in the registry.

Life of this trial

202120222023202420252026Registered2021-06-23Started2021-07-21Stopped2024-04-16Results posted2025-07-20

Vital statistics

Status
Terminated
Phase
Phase 3
Sponsor
AstraZeneca
Sponsor type
Industry
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Benralizumab; Placebo to Benralizumab
Participants
100
Sites
48
Countries
Argentina, Australia, Canada, China, Denmark, Germany, India, Italy, Philippines, Poland, Russia, South Korea and more

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.